Mainz Biomed N.V.

Company Overview

Business Model: Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer. Its flagship product, ColoAlert, is a colorectal cancer (CRC) screening test marketed in Europe. The company operates a clinical diagnostic laboratory and distributes IVD kits to third-party laboratories in Europe, having ceased direct-to-consumer sales in 2024 to focus on lab network expansion. Mainz Biomed N.V. also conducts research and development to diversify its product portfolio, including PancAlert for pancreatic cancer and a recently licensed blood-based test for pancreatic cancer. Revenue is primarily generated through the sale of IVD kits and diagnostic services to laboratories.

Market Position: The company operates in the cancer diagnostics segment, emphasizing early detection for improved patient outcomes and cost savings. Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death in men and women in the United States. Global CRC cases are projected to increase by 60% to over 2.2 million new cases and 1.1 million deaths by 2030. In Europe, the addressable market for CRC screening is estimated at 126 million individuals (based on a 65% participation rate among 194 million people over 50). In the United States, with new guidelines recommending screening from age 45, the addressable market is expected to grow from $3.7 billion to over $5.2 billion annually, encompassing 117 million individuals, projected to reach over 160 million within 10 years. Mainz Biomed N.V. competes with traditional screening methods like colonoscopies and Fecal Immunochemical Tests (FITs), as well as other non-invasive tests from companies such as Exact Sciences Corporation (Cologuard), Freenome Holdings, Inc., Geneoscopy Inc. (ColoSense), Guardant Health, Inc. (Shield), GRAIL, Inc. (Galleri), and Universal DX (Signal-C). Key competitive factors include accuracy, time-to-result, ease of use, executive team experience, and R&D capabilities.

Recent Strategic Developments:

• 2024 Restructuring: Mainz Biomed N.V. restructured its operations in July and October 2024 to focus on its ColoAlert business in Europe, the development of its next-generation product, and planning for the eAArly DETECT 2 clinical study in the United States. This involved a 65% reduction in personnel, reduced external consulting costs, and the sale of its European Oncology Lab GmbH business to a related party. Salaries for the CEO and CFO were also reduced by 60% and 50%, respectively.
• ColoAlert IP Acquisition: On February 15, 2023, the company acquired the intellectual property for the ColoAlert test from ColoAlert AS for $2 million cash (paid over four years), 300,000 ordinary restricted shares, and a revenue share of $1 per test sold for 10 years.
• Next-Generation CRC Product Development:
  • UdeS Biomarkers Acquisition: On February 15, 2023, Mainz Biomed N.V. exercised an option to acquire exclusive intellectual property rights to novel mRNA biomarkers (UdeS Biomarkers) from Socpra Sciences Santé Et Humaines S.E.C. for €25,000 cash and a 2% profit share of net sales of products using these biomarkers.
  • Clinical Studies: Initiated ColoFuture (international multi-center clinical study) and eAArly DETECT (U.S. multi-center study) to evaluate the integration of UdeS Biomarkers into its next-generation product.
  • Study Results: ColoFuture (October 2023) reported 94% sensitivity for CRC, 97% specificity, and 80% sensitivity for advanced adenoma (AA). eAArly DETECT (December 2023) reported 97% sensitivity for CRC, 97% specificity, and 82% sensitivity for AA.
  • FDA Pivotal Study: Planning reconAAsense, a prospective clinical study involving approximately 15,000 subjects from 150 sites across the United States, to support FDA premarket approval (PMA) for its next-generation CRC product.
• Pancreatic Cancer Program:
  • PancAlert: Ongoing government-funded research and development project for a stool-based screening test for pancreatic cancer.
  • Liquid Bioscience, Inc. License: In March 2025, acquired an exclusive license from Liquid Bioscience, Inc. to access a portfolio of novel mRNA biomarkers for a non-invasive blood test for pancreatic cancer, with a unilateral option to acquire exclusive global rights.

Geographic Footprint: Mainz Biomed N.V. is incorporated under Dutch law, with its corporate seat in Amsterdam, the Netherlands, and its registered office and principal place of business in Mainz, Germany. Substantially all of its operations are conducted in Germany. Its ColoAlert product is marketed and sold in various European markets, including Germany, the United Kingdom, Spain, Poland, Austria, Romania, Italy, and Israel. The company plans to expand its next-generation colorectal cancer screening product into the United States and further into Europe.

Cross-Border Operations: Mainz Biomed N.V. operates through wholly-owned subsidiaries: Mainz Biomed Germany GmbH and Mainz Biomed USA, Inc. (European Oncology Lab GmbH was sold to a related party in 2024). The company has acquired intellectual property and licensed biomarkers from entities in Norway, Canada (Université de Sherbrooke), and the United States (Liquid Bioscience, Inc.). Its multi-jurisdictional operations expose it to diverse legal and regulatory requirements, including health and safety standards, marketing regulations, anti-corruption laws, import/export controls, trade restrictions, tariffs, taxation, sanctions, immigration, data privacy (e.g., EU IVD-R, US FDA, CLIA, HIPAA), and labor relations.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 64.3% (2024) vs. 56.9% (2023)
• Operating Margin: -2091.3% (2024) (reflects significant operating losses relative to revenue)
• Net Margin: -2421.8% (2024) (reflects significant net losses relative to revenue)

Investment in Growth:

• R&D Expenditure: $5,839,033 (653.1% of revenue) in 2024, a decrease from $9,590,393 (1070.9% of revenue) in 2023. This decrease was primarily due to the completion of significant expenses related to the ColoFuture and eAArly DETECT feasibility studies in 2023.
• Capital Expenditures: $104,949 in 2024, a decrease from $1,198,841 in 2023, primarily due to higher capital expenditures in 2023 for office and lab space expansion.
• Strategic Investments:
  • Acquisition of ColoAlert intellectual property: $2 million cash (over four years), 300,000 ordinary restricted shares, and a revenue share of $1 per test sold for 10 years.
  • Acquisition of UdeS Biomarkers intellectual property: €25,000 cash and a 2% profit share of net sales.
  • License from Liquid Bioscience, Inc. for pancreatic cancer biomarkers: Fixed payments increasing upon milestones, with a royalty on future revenues if the option to acquire is exercised.
  • Government grants for R&D projects: $46,087 in 2024 and $27,741 in 2023 for multi-marker test for early detection of pancreatic cancer (PancAlert).

Currency Impact Analysis:

• Foreign exchange impact on revenue and earnings: Exchange differences arising from the translation of monetary items or their settlement are recognized in the statement of loss and comprehensive loss.
• Hedging strategies and effectiveness: Mainz Biomed N.V. does not hedge its currency exposure. It manages foreign currency risk by holding cash deposits in both U.S. dollars and Euro to match budgeted expenditures.
• Functional currency considerations: The functional currency of the company is the Euro (EUR). The reporting currency is the U.S. dollar. Exchange gains and losses arising from translation to the reporting currency are recorded in other comprehensive income (loss).

Business Segment Analysis

Genetic Diagnostic Testing

Financial Performance:

• Revenue: $893,991 (-0.17% YoY).
• Gross Profit: $574,883 (+12.8% YoY).
• Operating Margin: 64.3% (2024) vs. 56.9% (2023).
• Key Growth Drivers: The increase in gross profit and margin was attributable to increased ColoAlert sales through the lab network, which have a higher gross margin. ColoAlert sales through the lab network increased by 33% to $562,507 in 2024. The company's strategic decision to cease direct-to-consumer sales in 2024, which had lower margins, also contributed to the margin improvement. Future growth is anticipated from the commercialization of its next-generation colorectal cancer screening product in the United States and Europe, and the development of pancreatic cancer diagnostic tests.

Product Portfolio:

• ColoAlert: A CE-IVD certified multi-target stool DNA test for colorectal cancer screening, analyzing genetic anomalies and hidden blood. Initial studies showed 85% sensitivity and 92% specificity. The occult blood test component has been updated for improved accuracy. The test is currently validated on the Roche LightCycler 480 II, with plans to validate on additional real-time PCR instruments for broader market penetration.
• Next-Generation Colorectal Cancer Screening Test: Incorporates novel mRNA biomarkers (UdeS Biomarkers) acquired from Socpra Sciences Santé Et Humaines S.E.C. Clinical studies (ColoFuture and eAArly DETECT) demonstrated high effectiveness, with eAArly DETECT showing 97% sensitivity for CRC, 97% specificity, and 82% sensitivity for advanced adenoma. A pivotal FDA PMA study, reconAAsense, is planned for U.S. market authorization.
• PancAlert: A stool-based screening test for pancreatic cancer in early development, aiming to be the world's first Real-Time PCR-based multiplex detection of molecular-genetic biomarkers in stool samples. Key biomarker candidates include KRAS, mBMP3, NDRG4, and GNAS codon 201, with analysis supported by an artificial intelligence solution.
• Blood-Based Pancreatic Cancer Test: An exclusive license was acquired from Liquid Bioscience, Inc. in March 2025 for novel mRNA biomarkers for non-invasive detection of pancreatic cancer via a blood test. Studies showed 95% sensitivity and 98% specificity.

Market Dynamics:

• Competitive Positioning: Mainz Biomed N.V. differentiates itself through its focus on decentralized laboratory testing using established PCR methodology, contrasting with some competitors' centralized models and costlier technologies like next-generation sequencing.
• Key Customer Types: Primarily clinical reference laboratories and routine diagnostic laboratories in Europe.
• Regional Market Trends: The market is driven by the increasing incidence of CRC in younger populations and a global trend towards lowering screening ages (e.g., FDA recommending age 45). There is a significant unmet need for more sensitive non-invasive screening tools, particularly in Europe where screening participation rates are low.
• Regulatory Environment by Jurisdiction:
  • Europe: ColoAlert PCR kit is CE-IVD registered under the IVD-D. The sample collection kit is registered under the stricter IVD-R, and the company is evaluating steps for the PCR kit to meet IVD-R requirements (Class C device, requiring Notified Body review by TÜV Rheinland).
  • United States: Entry requires FDA market authorization, likely through a pre-market approval (PMA) for a Class III IVD, necessitating extensive clinical trials. The company will also be subject to CLIA, HIPAA, and various federal and state anti-fraud and abuse laws.

Geographic Revenue Distribution:

• Germany: $835,320 (93.4% of total revenue) in 2024. This includes $562,507 from the lab network (+33% YoY) and $272,813 from direct-to-consumer sales (-34% YoY, as this channel was ceased in 2024). An additional $61,569 in related party revenue was generated from the European Oncology Lab GmbH after its sale to a related party in 2024, likely Germany-based. The company's strategy in Germany focuses on expanding its footprint through direct sales to medical professionals (general practitioners, gastroenterologists, gynecologists, urologists) and partnerships with large laboratory chains.
• Other European Markets: Established connections in the United Kingdom, Spain, Poland, Austria, Romania, Italy, and Israel. The strategy targets markets accustomed to out-of-pocket payments for medical tests, while pursuing statutory reimbursement for the next-generation product. Specific revenue figures for these markets are not explicitly disclosed.
• United States: No revenue disclosed for 2024. Entry is planned with the next-generation product, pending FDA market authorization. The strategy involves selling test kits to CLIA-certified clinical laboratories or offering the test as a laboratory developed test via Mainz Biomed N.V.'s clinical laboratory.

International Operations & Geographic Analysis

Revenue by Geography:

International Business Structure:

• Subsidiaries:
  • Mainz Biomed Germany GmbH (Germany): Wholly-owned.
  • Mainz Biomed USA, Inc. (United States): Wholly-owned.
  • European Oncology Lab GmbH (Germany): Wholly-owned subsidiary of Mainz Biomed Germany GmbH, sold to a related party in 2024.
• Joint Ventures: No joint ventures are explicitly mentioned in the filing.
• Licensing Agreements:
  • Acquired exclusive intellectual property rights to UdeS Biomarkers from Socpra Sciences Santé Et Humaines S.E.C. (Canada).
  • Acquired an exclusive license from Liquid Bioscience, Inc. (United States) for novel mRNA biomarkers for pancreatic cancer detection.

Cross-Border Trade:

• Export Markets: ColoAlert PCR kits are manufactured in Mainz, Germany, and distributed to third-party laboratories across Europe.
• Import Dependencies: The company purchases most of its supplies "off-the-shelf" and maintains second-source suppliers to mitigate supply chain issues.
• Transfer Pricing: The company's international tax strategy includes considerations for transfer pricing risks, as mentioned in the regulatory section.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: The general meeting authorized the Board of Directors on May 31, 2024, to acquire fully paid-up ordinary shares until November 29, 2025, up to the maximum permitted by law and articles of association, at prices ranging from nominal value to 110% of the market price. No actual share repurchases were disclosed for 2024 or 2023.
• Dividend Payments: Mainz Biomed N.V. has never paid cash or stock dividends and does not intend to pay any in the foreseeable future, prioritizing the retention of future earnings for business operation and development. Any profits would first be applied to preferred shares, if outstanding.
• Dividend Yield: Not applicable, as no dividends are paid.
• Future Capital Return Commitments: No specific future capital return commitments beyond the authorized share repurchase program are disclosed.

Balance Sheet Position:

• Cash and Equivalents: $6,235,670 as of December 31, 2024, compared to $7,070,925 as of December 31, 2023.
• Total Debt: $2,125,254 as of December 31, 2024, compared to $5,966,594 as of December 31, 2023. This includes convertible debt and silent partnership agreements.
• Net Cash Position: $4,110,416 as of December 31, 2024, compared to $1,104,331 as of December 31, 2023.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Convertible Promissory Notes mature one year from issuance, with monthly cash payments required upon a "Trigger Event" (trading price below Floor Price for five of seven consecutive trading days). Silent partnership agreements have various maturities, with some due by December 31, 2025, and June 30, 2025.

Cash Flow Generation:

• Operating Cash Flow: $(17,090,011) in 2024, an improvement from $(21,938,845) in 2023, primarily due to a reduction in net loss.
• Free Cash Flow: $(17,194,960) in 2024 (Operating Cash Flow less Capital Expenditures), compared to $(23,137,686) in 2023.
• Cash Conversion Metrics: Not explicitly disclosed.

Currency Management:

• Cash holdings by major currencies: A portion of cash balances is held in Euro to cover estimated operating needs for three to twelve months, with the remainder held in U.S. dollars, which is the company's reporting currency and the currency for its largest cash outlays.
• Natural hedging through operational diversification: Not explicitly detailed, but operations in both Euro and U.S. dollar-denominated markets may provide some inherent diversification.
• Financial hedging instruments and strategies: Mainz Biomed N.V. does not hedge its currency exposure.

Operational Excellence

Production & Service Model: Mainz Biomed N.V. develops and sells IVD tests for early cancer detection. It manufactures its ColoAlert PCR kits at its facility in Mainz, Germany. While it previously operated a clinical diagnostic laboratory for direct-to-consumer sales, it has strategically shifted its focus to distributing IVD kits to third-party laboratories in Europe. For its planned entry into the U.S. market, the company intends to employ a decentralized product and marketing strategy, selling its next-generation test as a kit to CLIA-certified clinical laboratories.

Global Supply Chain Architecture: Key Suppliers & Partners:

• Supplies: The company purchases most of its supplies "off-the-shelf" at market rates and maintains second-source suppliers to mitigate potential supply issues. It plans to establish a safety stock from primary suppliers.
• Technology Partners:
  • ColoAlert AS (Norway): Original licensor of the ColoAlert test, from which Mainz Biomed N.V. acquired the intellectual property in February 2023.
  • Socpra Sciences Santé Et Humaines S.E.C. (Canada): Source of the UdeS Biomarkers, whose intellectual property was acquired in February 2023 for integration into the next-generation CRC product.
  • Liquid Bioscience, Inc. (United States): Partner for the exclusive license to novel mRNA biomarkers for a blood-based pancreatic cancer test, acquired in March 2025.
  • Roche: ColoAlert is currently validated on the Roche LightCycler 480 II, and Mainz Biomed N.V. plans to validate the test on additional real-time PCR instruments.

Facility Network:

• Manufacturing: The company's primary manufacturing facility for ColoAlert PCR kits is located in Mainz, Germany.
• Research & Development: R&D activities are conducted at the Mainz, Germany facility, which housed 26 employees and independent contractors as of December 31, 2023.
• Distribution: Distribution primarily relies on partnerships with third-party laboratories in Europe, leveraging their existing customer bases and sales teams.

Operational Metrics: Mainz Biomed N.V. has implemented an ISO standard 13485 quality management system for the design and manufacture of medical devices, addressing regulatory requirements, control systems, inspection, traceability, device design, risk, and performance criteria. Specific capacity utilization, efficiency measures, or quality indicators are not explicitly disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: In Germany, ColoAlert is directly offered to medical professionals involved in colorectal cancer screening, including general practitioners, gastroenterologists, gynecologists, and urologists.
• Channel Partners: The company partners with laboratories, including approximately 12 lab chains in Germany that process a significant portion of FIT tests. This strategy aims to leverage partners' broad physician networks and sales teams for cost-effective market penetration and accelerated product rollouts.
• Digital Platforms: Previously, Mainz Biomed N.V. offered ColoAlert directly to consumers via an online portal in Germany, but this direct-to-consumer sales channel was ceased in 2024.
• United States: For its planned U.S. market entry, the company intends to sell its next-generation test as a kit to CLIA-certified clinical laboratories or offer it as a laboratory developed test through its own clinical laboratory.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: The company's current customers are primarily laboratories in Germany, including some of the largest chains.
• Strategic Partnerships: Partnerships with significant lab chains and independent laboratories are central to its market penetration strategy in Europe.
• Customer Concentration:
  • For the year ended December 31, 2024, one customer accounted for approximately 57% of total revenue.
  • For the year ended December 31, 2023, two customers accounted for approximately 21% of total revenue.
  • For the year ended December 31, 2022, four customers accounted for approximately 38% of total revenue.
  • As of December 31, 2024, accounts receivable consisted of two customers, accounting for 100% of the balance.

Regional Market Penetration:

• Germany: Remains a focal market in 2024, with efforts to enlarge its footprint through direct sales, channel partnerships, and increased product visibility.
• Growth Markets: Mainz Biomed N.V. is progressively extending operations to other German-speaking territories and selected international markets (e.g., UK, Spain, Poland, Austria, Romania, Italy, Israel) that are accustomed to personal health expenditures, adapting commercial strategies to local healthcare payment practices.
• United States: The company is actively exploring the required clinical and regulatory path for its next-generation product to enter the U.S. market, aiming to fill a gap in the large reference laboratory and health network sectors for CRC screening options.

Competitive Intelligence

Global Market Structure & Dynamics

Industry Characteristics: The cancer diagnostics industry is characterized by a critical need for early detection, which significantly improves survival rates and reduces treatment costs, particularly for colorectal cancer (CRC). CRC is a major global health burden, with cases expected to increase by 60% to over 2.2 million new cases and 1.1 million deaths by 2030. Key trends include a shift towards lowering screening ages (e.g., FDA recommending age 45) due to increasing CRC prevalence in younger populations, and a demand for more sensitive, non-invasive screening tools to improve participation rates, which are currently low in many regions (e.g., less than 15% in the EU for adults aged 45-74). The addressable market in the United States alone is projected to grow from $3.7 billion to over $5.2 billion annually.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Exact Sciences Corporation: A leading molecular diagnostics firm, offering Cologuard, a fecal DNA-based CRC screening test with 92% sensitivity and 87% specificity, and an average reimbursement of $500. Exact Sciences Corporation utilizes a centralized, in-house laboratory model.
• Freenome Holdings, Inc.: Developing a blood-based CRC screening test using a multimodal data approach, with pivotal FDA study results and clearance anticipated within the next 12 months.
• Geneoscopy Inc.: Offers ColoSense, a stool RNA test for gastrointestinal health, which has shown promising sensitivity and specificity for detecting CRC and advanced adenomas in clinical trials. An FDA decision on pre-marketing approval is expected in 2024.
• Guardant Health, Inc.: Known for its liquid biopsy technology, Guardant Health, Inc.'s Shield blood test detects colorectal cancer signals, including circulating tumor DNA, with high sensitivity and specificity. A commercial launch in the U.S. is targeted for 2024.
• GRAIL, Inc.: Markets Galleri, a blood test leveraging next-generation sequencing technology to detect over 50 types of cancer, intended for use alongside traditional screening methods, priced at $959.
• Universal DX: A Spanish entity developing Signal-C, a liquid biopsy screening test for CRC, currently undergoing validation with FDA approval in process.

Regional Competitive Dynamics:

• Europe: Mainz Biomed N.V. competes with the established colonoscopy (high accuracy, low patient acceptance) and FIT tests (high participation with centralized invitation, lower sensitivity). The company aims to provide a more sensitive non-invasive option.
• United States: The U.S. market is significantly influenced by Exact Sciences Corporation's Cologuard. Mainz Biomed N.V. seeks to differentiate itself by offering its next-generation test as a kit to clinical laboratories, thereby addressing a gap in the market for decentralized CRC screening options within large reference laboratory and health network sectors.

Risk Assessment Framework

Strategic & Market Risks

• Global Market Dynamics: Operations and performance are significantly impacted by global economic conditions, including geopolitical developments (e.g., wars in Ukraine and the Middle East), potential global economic phenomena (e.g., tariffs), and general financial market turbulence (e.g., COVID-19 pandemic). Such uncertainties can lead to customers postponing purchases, supply chain disruptions, and price fluctuations.
• Technology Disruption: The company faces intense competition from other entities developing and offering diagnostic tests. Competitors may introduce new, safer, more accurate, or more cost-effective diagnostic tests that could render Mainz Biomed N.V.'s products obsolete or non-competitive. Failure to obtain and enforce patents or protect trade secrets could allow competitors to use its technology.
• Customer Concentration: A significant portion of revenue is derived from a limited number of customers (e.g., one customer accounted for approximately 57% of 2024 revenue). A decrease in demand or discontinuation of partnerships by these key customers could materially adversely affect financial performance.

Operational & Execution Risks

• Global Supply Chain Vulnerabilities: The company relies on "off-the-shelf" supplies and, while it has second-source suppliers, disruptions could occur. Facilities and equipment, particularly at its Mainz, Germany location, are vulnerable to natural or man-made disasters, which could render them inoperable and disrupt testing services, leading to customer loss or reputational harm.
• Regional Disruptions: Changes in trade policy, tariffs, and import/export regulations could increase operating costs, impose restrictions on operations, or require additional funds for compliance, adversely impacting financial condition.

Financial & Regulatory Risks

• Currency & Financial Risks:
  • Foreign Exchange: A substantial percentage of operations are conducted in Europe, exposing the company to exchange rate risk between the U.S. dollar and the Euro. The company does not hedge its currency exposure, making it vulnerable to volatility in exchange rates, which could impact product costs and sales.
  • Interest Rate Risk: While current financial liabilities carry fixed rates, future variable-rate liabilities could expose the company to interest rate fluctuations.
  • Credit & Liquidity: Mainz Biomed N.V. is an early revenue stage company with recurring losses, an accumulated deficit of $91.0 million, and negative cash flows from operating activities ($17.1 million in 2024). These factors raise substantial doubt about its ability to continue as a going concern, necessitating future debt and/or equity financings.
• Regulatory & Compliance Risks:
  • Multi-Jurisdictional Compliance: The company is subject to numerous and sometimes conflicting legal and regulatory requirements across its operating countries, including health and safety, marketing, anti-corruption, import/export controls, trade restrictions, taxation, sanctions, immigration, data privacy (e.g., HIPAA), and labor relations. Violations could result in significant fines, criminal sanctions, and reputational damage.
  • Trade Regulations: Changes in laws and policies governing foreign trade could adversely affect the business.
  • Tax Regulations: The company is subject to Dutch and German tax laws. While currently considered solely tax resident in Germany for German-Dutch tax treaty purposes (exempting from Dutch dividend withholding tax), this status could change. International tax planning and transfer pricing risks are also relevant.

Geopolitical & External Risks

• Country-Specific Risks: As a Dutch-incorporated company with substantial assets and management outside the U.S., U.S. investors may face difficulties enforcing judgments in U.S. courts. Global economic conditions and geopolitical developments can materially impact demand for products and services.
• Regulatory Changes: Healthcare policy is subject to extensive discussion and change in many national, regional, and local governments. In Europe, the new In-Vitro Diagnostics Regulation (IVD-R) imposes more stringent requirements, including direct review and approval by Notified Bodies for most IVDs. In the U.S., obtaining FDA market authorization for its next-generation product is critical but involves costly, lengthy, and uncertain clinical studies and regulatory processes.

Innovation & Technology Leadership

Research & Development Focus: Global R&D Network: Mainz Biomed N.V.'s research and development team is primarily located at its facilities in Mainz, Germany, comprising 26 employees and independent contractors as of December 31, 2023. Innovation Pipeline:

• Next-Generation Colorectal Cancer Screening Product: The company is focused on integrating novel mRNA biomarkers (UdeS Biomarkers) into its next-generation product to enhance ColoAlert's technical profile, specifically to expand its capability to identify advanced adenomas and increase diagnostic sensitivity and specificity for CRC. This involves ongoing international multi-center clinical studies (ColoFuture in Europe and eAArly DETECT in the U.S.) and planning for a pivotal FDA PMA study (reconAAsense).
• Pancreatic Cancer Diagnostic Tests: Mainz Biomed N.V. is in the early stages of developing PancAlert, a stool-based screening test for pancreatic cancer, aiming for a Real-Time PCR-based multiplex detection of molecular-genetic biomarkers. Additionally, the company has licensed a portfolio of novel mRNA biomarkers from Liquid Bioscience, Inc. for a non-invasive blood-based test for pancreatic cancer.

Intellectual Property Portfolio:

• Patent Strategy: The company primarily relies on trade secrets, know-how, and technology to protect its intellectual property. Patent applications are pending related to the UdeS Biomarkers in the U.S. PTO and through the International Patent System. Mainz Biomed N.V. intends to file additional patent applications to protect intellectual property derived from successful research and development efforts for its next-generation colorectal cancer screening test and PancAlert.
• Licensing Programs: The company has acquired exclusive licenses for key biomarker technologies, including the UdeS Biomarkers from Socpra Sciences Santé Et Humaines S.E.C. and novel mRNA biomarkers for pancreatic cancer from Liquid Bioscience, Inc.
• IP Litigation: The company acknowledges the risk of costly and time-consuming litigation to enforce and determine the scope of its proprietary rights, and the potential for competitors to sue to avoid or delay market entry.

Technology Partnerships:

• Strategic Alliances: Key partnerships include those with Université de Sherbrooke (Canada) for the UdeS Biomarkers and Liquid Bioscience, Inc. (United States) for pancreatic cancer biomarkers.
• Research Collaborations: The company's R&D efforts, including the PancAlert project, have received government grants from the German Federal Ministry of Research and Education.

Leadership & Governance

Executive Leadership Team

International Management Structure: The executive leadership team includes individuals with global experience (Guido Baechler) and regional expertise (Dr. Chris von Toerne, based in Mainz, Germany). The CEO and CFO are based in the U.S. The company's management structure supports its multi-jurisdictional operations, with regional leadership and reporting relationships implied by its European and planned U.S. market focus.

Board Composition: The Board of Directors consists of four members: one executive director (Guido Baechler) and three non-executive directors (Dr. Heiner Dreismann, Hans Hekland, and Gregory Tibbitts). All three non-executive directors are deemed "independent" under Nasdaq Stock Market LLC rules. The board's composition includes individuals with international expertise (Dr. Dreismann, Hans Hekland, Guido Baechler) and financial expertise (Gregory Tibbitts, who is an "audit committee financial expert"). The board operates with three committees: an Audit Committee, a Compensation Committee, and a Nominating Committee, each governed by a charter. An informal Strategic Advisory Board, comprising Dr. Soren Thestrup-Nielsen, Dr. Michele Pedrocchi, and Dr. Rainer Metzger, provides strategic guidance.

Regulatory Environment & Compliance

Multi-Jurisdictional Regulatory Framework: Primary Regulatory Environments:

• Netherlands: Mainz Biomed N.V. is incorporated under Dutch law and adheres to Dutch corporate governance rules, which differ from certain Nasdaq requirements (e.g., regarding quorum, proxy solicitation, and shareholder approval for certain security issuances).
• Germany: As the location of its principal place of business and substantial operations, the company is subject to German tax laws. For purposes of the German-Dutch tax treaty, it is currently considered solely tax resident in Germany, which in principle exempts it from Dutch dividend withholding tax.
• European Union:
  • IVD-D (Directive 98/79/EC): The ColoAlert PCR kit is CE-IVD registered under this directive.
  • IVD-R (Regulation EU 2017/746): This regulation, which replaced the IVD-D, became fully effective on May 26, 2022. The ColoAlert sample collection kit has been successfully registered under IVD-R. The company is evaluating the necessary steps for its ColoAlert PCR kit to meet IVD-R requirements, as it is classified as a Class C device, necessitating direct review and approval by a Notified Body (TÜV Rheinland has been selected).
• United States:
  • FDA: The company intends to seek U.S. Food and Drug Administration (FDA) market authorization for its next-generation colorectal cancer product, which will likely require a pre-market approval (PMA) for a Class III in vitro diagnostic device. This involves successfully completing extensive clinical trials (e.g., reconAAsense study).
  • CLIA: If Mainz Biomed N.V. operates clinical laboratories in the United States, it will be subject to federal Clinical Laboratory Improvement Amendments (CLIA) requirements, which impose certification and quality standards.
  • HIPAA: The company may be subject to the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and comparable state laws, which establish comprehensive protection for the privacy and security of health information.
  • Anti-fraud and Abuse Laws: In the U.S., the company will be subject to federal and state anti-fraud and abuse laws, including the Anti-Kickback Statute, the Stark Law (physician self-referral prohibition), federal false claims and civil monetary penalties laws, and the Physician Payment Sunshine Act.

Cross-Border Compliance:

• Export Controls: The company's global operations expose it to various import/export controls and trade restrictions.
• Sanctions Compliance: Mainz Biomed N.V. is subject to applicable restrictions under sanctions and measures pursuant to United Nations resolutions, European Union regulations, and the Dutch Sanctions Act 1977.
• Anti-Corruption: The company is subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (FCPA) and local anti-bribery laws, and maintains compliance programs.
• Cybersecurity: Mainz Biomed N.V. has established policies, processes, and systems for assessing, identifying, and managing material risks from cybersecurity threats, integrated into its overall risk management. This includes a Data Protection Officer (DPO), regular technical safeguards, use of external service providers, employee training, and agreements with third-party service providers. The Board of Directors, with the assistance of the Audit Committee, oversees the company's cybersecurity programs and strategies.

International Tax Strategy:

• Transfer Pricing: The company acknowledges transfer pricing risks and the need for inter-company pricing policies and documentation requirements.
• Tax Treaties: The German-Dutch tax treaty currently results in Mainz Biomed N.V. being considered solely tax resident in Germany, which generally exempts it from Dutch dividend withholding tax.
• BEPS Compliance: The European Directive Mandatory Disclosure Rules (BEPS compliance) may introduce future notification requirements for cross-border tax arrangements.

Currency Management & Financial Strategy

Multi-Currency Operations: Currency Exposure:

Hedging Strategies:

• Transaction Hedging: Mainz Biomed N.V. does not hedge its currency exposure. It incurs currency transaction risk whenever it enters into purchase or sale transactions using a currency other than the Euro (its functional currency).
• Translation Hedging: Exchange differences arising from the translation of the Euro functional currency to the U.S. dollar presentation currency are recorded in other comprehensive income (loss). No specific financial instruments for translation hedging are disclosed.
• Economic Hedging: Not explicitly detailed, but the company's strategy of holding cash in both U.S. dollars and Euro to match budgeted expenditures, alongside its multi-jurisdictional operations, may provide some inherent economic hedging.